TECHSTARS
30.6.2021 11:02:12 CEST | Business Wire | Press release
Techstars , the worldwide network that helps entrepreneurs succeed, today announced a new accelerator program, the Launchpool Web3 Techstars Accelerator. The program will work with entrepreneurs building blockchain technology and tokenisation protocols driving towards the decentralised future of finance.
The program will run in partnership with Alphabit Fund, the first regulated cryptocurrency and digital asset investment fund, and Launchpool, a regulatory compliant investment platform that offers private seed guaranteed investment opportunities to its member community.
Techstars maintains notable experience and expertise in the blockchain space, with many strong blockchain companies in the Techstars portfolio including Chainalysis, who last week announced a $100 million round and valuation of $4.2 billion.
“Blockchain technology has the potential to shift the control of monetary value and information and disrupt global business processes, as the internet did in the early 2000s,” said Techstars General Manager Gagan Bhatia. “Working with Alphabit and the Launchpool community to support leading companies in this space is an incredible opportunity and an investment in the decentralised economy of the future.”
Located in London, the Launchpool Web3 Techstars Accelerator will work with ten startups each year over a three-month period where startups will receive funding, hands-on mentorship from Techstars, Alphabit, and Launchpool, access to curated workshops and resources, admittance to the Techstars global network for life, and exposure to a minimum viable community. Applications for the Launchpool Web3 Techstars Accelerator will open on September 13, 2021 and be accepted through December 1, 2021. The first year of the accelerator will operate from March 2022 through June 2022.
“Launchpool is thrilled to be partnering with Techstars and Alphabit to bring the Launchpool Web3 Techstars Accelerator to the crypto world. As firm believers in a multichain future, and being passionate about mainstream adoption, this first-of-its-kind accelerator is proud to be chain agnostic,” said Shane McQuillian, VP Strategy, Alphabit. “With a killer lineup of mentors that represent a diverse cross-section of the blockchain space to work together, we feel we can really help founders and BUIDLers bring something truly innovative to the wider crypto industry.”
Startups interested in the program are encouraged to learn more by visiting the Launchpool Web3 Techstars Accelerator page or expressing interest here . Corporations and investors interested in partnership opportunities with Techstars can get in touch with Will Robinson , SVP of Global Sales, or learn more at techstars.com/corporations .
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,500 companies with a combined market cap of more than $200B. www.techstars.com
About Alphabit
One of the first regulated crypto asset funds, Alphabit has forged a reputation for investing in companies at the cutting edge of the blockchain revolution. Alphabit believes, supports, and invests in the decentralised economy of the future, with a generous portfolio of startups, protocols, and DeFi solutions that address an alternative to the traditional financial systems. www.alphabit.fund
About Launchpool
LaunchPool is a regulatory compliant initiative which was started in 2020, by the Alphabit Digital Currency Fund with the aim of providing fair guaranteed access to early stages of project raises to the retail community. With the ethos of ‘Egalitarian Investment’, Launchpool counts over 35,000 investors across the world who believe in the idea of being your own VC, while supporting the startups ecosystem with a minimum viable community, resources, access to funding opportunities, and enabling partnerships across the blockchain ecosystem. www.launchpool.xyz
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005204/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom